| Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) (NCT06525675) | MedSIR | 2022-07-18 |
| IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors (NCT05076591) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-06-20 |
| The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis (NCT05431504) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-06-01 |
| A Study in Patients With Advanced Breast Cancer (NCT04942054) | Sun Pharma Advanced Research Company Limited | 2022-05-20 |
| Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer (NCT06098599) | Luye Pharma Group Ltd. | 2022-05-17 |
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (NCT05227131) | MedSIR | 2022-05-15 |
| A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer (NCT04655573) | Duke University | 2022-04-07 |
| A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer (NCT05274893) | CSPC Ouyi Pharmaceutical Co., Ltd. | 2022-03-31 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer (NCT04826016) | MedSIR | 2022-03-16 |
| A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer (NCT05257395) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-03-14 |
| Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant (NCT04862143) | Novartis Pharmaceuticals | 2022-03-08 |
| This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. (NCT05439499) | Ahon Pharmaceutical Co., Ltd. | 2022-03-02 |
| Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer (NCT05255523) | Fujian Medical University Union Hospital | 2022-02-20 |
| RCT of CBD for Anxiety in Advanced Breast Cancer (NCT04482244) | Dana-Farber Cancer Institute | 2022-01-19 |
| A Study of Lerociclib in Participants With Advanced Breast Cancer (NCT05085002) | EQRx, Inc. | 2021-12-21 |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (NCT05216432) | Relay Therapeutics, Inc. | 2021-12-08 |
| A Study of GC101 TIL in Advanced Breast Cancer (10hospital) (NCT05142475) | Shanghai Juncell Therapeutics | 2021-11-19 |
| A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer (NCT05077449) | Xuanzhu Biopharmaceutical Co., Ltd. | 2021-11-16 |
| Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (NCT04316169) | Medical College of Wisconsin | 2021-10-21 |
| Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap (NCT05156619) | Hadassah Medical Organization | 2021-09-26 |
| Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer (NCT05173103) | University of Milano Bicocca | 2021-09-24 |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (NCT05063786) | Spanish Breast Cancer Research Group | 2021-09-14 |
| PFMT Educational Intervention for Patients With Advancer Breast Cancer (NCT04953377) | Onkologikoa | 2021-09-02 |
| Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib (NCT05020964) | Chinese Academy of Medical Sciences | 2021-08-20 |
| Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer (NCT05047848) | Liaoning Cancer Hospital & Institute | 2021-08-18 |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer (NCT04924699) | Shanghai Miracogen Inc. | 2021-06-30 |
| A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer (NCT05337657) | Genor Biopharma Co., Ltd. | 2021-06-02 |
| Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance (NCT04728035) | CSPC Ouyi Pharmaceutical Co., Ltd. | 2021-05-31 |
| A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. (NCT04733417) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-26 |
| Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency (NCT04892693) | Seoul National University Hospital | 2021-05-25 |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (NCT04965766) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-05-11 |
| CB-103 Plus NSAI In Luminal Advanced Breast Cancer (NCT04714619) | MedSIR | 2021-05-06 |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer (NCT04524000) | Novartis Pharmaceuticals | 2021-01-08 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (NCT04541225) | Nuvation Bio Inc. | 2020-12-08 |
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors (NCT04222413) | National Cancer Institute (NCI) | 2020-10-27 |
| HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer (NCT03685331) | Abramson Cancer Center at Penn Medicine | 2020-10-15 |
| First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (NCT04408118) | MedSIR | 2020-10-05 |
| Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (NCT04653740) | Centre Oscar Lambret | 2020-09-08 |
| Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer (NCT04436393) | Guardant Health, Inc. | 2020-07-02 |
| DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease (NCT04420598) | MedSIR | 2020-05-25 |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy (NCT04030728) | Onco Medical Consult GmbH | 2020-03-01 |
| Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (NCT05530057) | Seoul National University Hospital | 2020-02-18 |
| A Phase I Study of LX-039 Tablets (NCT04097756) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2020-01-07 |
| Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (NCT04227327) | University of Milano Bicocca | 2020-01-07 |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (NCT04188548) | Eli Lilly and Company | 2019-12-10 |
| FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (NCT06193525) | Erasmus Medical Center | 2019-09-16 |
| Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients (NCT04456855) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2019-09-01 |
| A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (NCT03966898) | Jiangsu HengRui Medicine Co., Ltd. | 2019-07-19 |
| Phase I Study of BEBT-209 in Women With Advanced Breast Cancer (NCT06047184) | BeBetter Med Inc | 2019-07-15 |
| A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (NCT03927456) | Jiangsu HengRui Medicine Co., Ltd. | 2019-06-13 |
| A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients (NCT04004910) | Immunicom Inc | 2019-05-31 |
| A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics (NCT03850873) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-05-20 |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer (NCT03524261) | Fuda Cancer Hospital, Guangzhou | 2019-05-20 |
| PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer (NCT05812326) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2019-05-17 |
| Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer (NCT03931551) | MedSIR | 2019-04-30 |
| Safety and Pharmacokinetics of ODM-209 (NCT03878823) | Orion Corporation, Orion Pharma | 2019-04-17 |
| PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (NCT03809988) | MedSIR | 2019-04-05 |
| A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (NCT03811418) | iOMEDICO AG | 2019-01-01 |
| Plasmodium Immunotherapy for Breast and Liver Cancers (NCT03474822) | CAS Lamvac Biotech Co., Ltd. | 2018-08-10 |
| Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA) (NCT03829306) | Spanish Breast Cancer Research Group | 2018-06-12 |
| A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (NCT04539496) | Sihuan Pharmaceutical Holdings Group Ltd. | 2018-05-22 |
| Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer (NCT03538171) | Taizhou EOC Pharma Co., Ltd. | 2018-05-15 |
| G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer (NCT03455270) | G1 Therapeutics, Inc. | 2018-05-09 |
| A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (NCT03481998) | Jiangsu HengRui Medicine Co., Ltd. | 2018-03-22 |
| Hypo-Fractionated Radiotherapy in Breast Cancer (NCT03669497) | Tata Medical Center | 2018-01-02 |
| Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (NCT03205761) | Spanish Breast Cancer Research Group | 2017-10-23 |
| A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (NCT03312738) | Novartis Pharmaceuticals | 2017-09-15 |
| Bioinformation Therapy for Breast Cancer (NCT03240224) | Fuda Cancer Hospital, Guangzhou | 2017-09-02 |
| Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC (NCT03025880) | Spanish Breast Cancer Research Group | 2017-06-28 |
| A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors (NCT03125746) | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 2017-06-12 |
| Clinical Study of Decitabine and Paclitaxel Combination Therapy (NCT03282825) | Dong Wha Pharmaceutical Co. Ltd. | 2017-03-28 |
| "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer (NCT03072992) | National Center of Oncology, Armenia | 2017-03-20 |
| Metronomic PLD in Patients With Primary Endocrine Resistant ABC (NCT03071926) | Fudan University | 2017-03-01 |
| Palbociclib in Real World Practice (NCT03280303) | Pfizer | 2017-01-04 |
| A Study of RC48-ADC in Subjects With Advanced Breast Cancer (NCT03052634) | RemeGen Co., Ltd. | 2016-12-23 |
| The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial (NCT03182634) | Institute of Cancer Research, United Kingdom | 2016-12-15 |
| Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer (NCT06926088) | The First Affiliated Hospital with Nanjing Medical University | 2016-12-01 |
| Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 (NCT02952729) | Mersana Therapeutics | 2016-11-21 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast (NCT03047889) | Chinese Academy of Medical Sciences | 2016-04-01 |
| A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer (NCT02599363) | Abramson Cancer Center at Penn Medicine | 2016-01-01 |
| Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (NCT02499146) | Pfizer | 2015-09-11 |
| Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors (NCT02401347) | Melinda Telli | 2015-08-01 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (NCT02580448) | Innocrin Pharmaceutical | 2015-08-01 |
| Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (NCT02422615) | Novartis Pharmaceuticals | 2015-06-09 |
| Cambridge Brain Mets Trial 1 (NCT02768337) | Cambridge University Hospitals NHS Foundation Trust | 2015-03-10 |
| Patterns of Prescribing and Monitoring of Palbociclib (NCT03285568) | Rush University Medical Center | 2015-02-03 |
| A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer (NCT02091960) | Astellas Pharma Global Development, Inc. | 2014-09-05 |
| Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients (NCT02027376) | Spanish Breast Cancer Research Group | 2014-05-01 |
| Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer (NCT02069093) | Novartis Pharmaceuticals | 2014-05-01 |
| Halaven Patient Registry (Metastatic Breast Cancer, MBC) (NCT03245112) | Chang Gung Memorial Hospital | 2014-03-03 |
| Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations (NCT01989546) | National Cancer Institute (NCI) | 2014-02-04 |
| Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer (NCT01836640) | Dartmouth-Hitchcock Medical Center | 2013-12-01 |
| Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer (NCT01876238) | Case Comprehensive Cancer Center | 2013-05-01 |
| A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer (NCT01931943) | Qilu Pharmaceutical Co., Ltd. | 2013-04-01 |
| Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients (NCT04304352) | European Institute of Oncology | 2011-07-29 |
| A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer (NCT00915369) | Fresenius Kabi Oncology Ltd. | 2009-03-01 |
| Level of HER2-neu Gene Amplification an Response to Trastuzumab (NCT00874146) | Istituto Clinico Humanitas | 2009-03-01 |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer (NCT00777101) | Puma Biotechnology, Inc. | 2009-02-04 |